Part,  Chapter, Paragraph

  1    -,     1            |             the European Commission D. G. Health and Consumers (
  2    -,     1            |           Antonella Calabrò, Marina D’Avanzo and Paola Marini
  3    I,     2. 10.  3    |      innovation for the uptake of R&D.~Launching of a public debate
  4    I,     2. 10.  4(18)|                           De Scioli D. (2005). Differatiating
  5    I,     2. 10.  4    |         proprietary solutions and R&D resources can be created
  6    I,     3.  4        |             NIDI, Den Haag.~ ~Bloom D E, Trussell J (1984): What
  7   II,     4.  3        |     Montpellier, EHEMU.~ ~Kung, H., D. Hoyert, et al. (2007):
  8   II,     4.  3        |            6): 590-597.~ ~Sullivan, D. F. (1971): A single index
  9   II,     5.  2.  6    |        Karvonen MJ, Kimura N, Lekos D, Monti M, Puddu V, Taylor
 10   II,     5.  2.  6    |            MP, Feskens EJ, Kromhout D (1996). Blood pressure and
 11   II,     5.  2.  6    |          1862.~Stamler J, Wentworth D, Neaton JD (1986). Is relationship
 12   II,     5.  2.  6    |         Donnell CJ, Kannel WB, Levy D (2001). Impact of high-normal
 13   II,     5.  2.  7    |             H, Sans S, and Kromhout D (2006): Dynamics of cardiovascular
 14   II,     5.  2.  7    |        Trojani M, Panico S, Vanuzzo D, Pilotto L, Cesana G, Ferrario
 15   II,     5.  2.  7    |             Donfrancesco C, Vanuzzo D, Chiodini P, Cesana G, Ferrario
 16   II,     5.  2.  7    |            S, Kesteloot H, Kromhout D on behalf of the Task Force (
 17   II,     5.  2.  7    |             M, Asplund K, rastenyte D, Kuulasma K, Vanuzzo D,
 18   II,     5.  2.  7    |    rastenyte D, Kuulasma K, Vanuzzo D, Tuomilehto J for the WHO
 19   II,     5.  2.  7    |           Tunstall-Pedoe H, Vanuzzo D, Hobbs M et al for the WHO
 20   II,     5.  2.  7    |         Unal B, Critchley JA, Fidan D, Capewell S (2005): Life-Years
 21   II,     5.  3.  9    |      Santaquilani M, Roazzi P, Lisi D, EUROCARE Working Group (
 22   II,     5.  4.  8    |             13(4), 245. 2001.~Boyle D, Cunningham S, Sullivan
 23   II,     5.  5.  1    |               Bille-Brahe U, De Leo D et al. (2004). Suicidal
 24   II,     5.  5.  2    |         Surr C, Boyle G and Brooker D (2005): Summary report for
 25   II,     5.  5.  3    |             7. References~Alexander D, Rigby M, (in press, due
 26   II,     5.  5.  3    |    Adolescents, in press.~Alexander D, Rigby M, Frazzica R.G,
 27   II,     5.  5.  3    |            March 2008).~Berkman, N. D.; Lohr, K. N.; Bulik, C.
 28   II,     5.  5.  3    |       Leclercq C, Kafatos A, Molnar D, Marcos A, Castillo M, Dallongeville
 29   II,     5.  5.  3    |            95.~Hoek H W, van Hoeken D, (2003): Review of the Prevalence
 30   II,     5.  5.  3    |             63-71.~Fors BM, Isacson D, Bingefors K, Widerlöv B (
 31   II,     5.  5.  3    |       Neurosci 254(2):117-28.~Healy D, Harris M, Tranter R, Gutting
 32   II,     5.  5.  3    |         Terwilliger JD, Lichtermann D, Makikyro T, Suvisaari J,
 33   II,     5.  5.  3    |              Salokangas RK, Linszen D, Birchwood M, Juckel G,
 34   II,     5.  5.  3    |              161-7.~Knapp M, McDaid D, Mossialos E, Thornicroft
 35   II,     5.  5.  3    |            PH, Tsai J, Yanos P, Roe D (2007): Associations of
 36   II,     5.  5.  3    |            1991.~Mathers CD, Loncar D (2006): Projections of Global
 37   II,     5.  5.  3    |            2511-2518.~Saha S, Chant D, McGrath J (2005): A systematic
 38   II,     5.  5.  3    |            2(5):e141.~Saha S, Chant D, McGrrath J (2007): A systematic
 39   II,     5.  5.  3    |          Shorvon S, Perucca E, Fish D, Dodson E.) Oxford, Blackwell
 40   II,     5.  5.  3    |          Shorvon S, Perucca E, Fish D, Dodson E.) Oxford, Blackwell
 41   II,     5.  5.  3    |            253.~Fraser RT, Clemmons D, Trejo W, Temkin NR (1983):
 42   II,     5.  5.  3    |             362.~Taylor J, Chadwick D, Johnson T (1996): Risk
 43   II,     5.  5.  3    |              Vignatelli L, Tonon C, DAlessandro R, on behalf
 44   II,     5.  5.  3    |         public awareness about MS; (d) the impact of different
 45   II,     5.  5.  3    |          level, among which vitamin D status with diet and sun
 46   II,     5.  5.  3    |              If sunlight or vitamin D are major environmental
 47   II,     5.  5.  3    |           remissions and plateaus; (d) primary-progressive MS (
 48   II,     5.  5.  3    |       Higginson I, Pitschnau-Michel D, Voltz D (2006) Position
 49   II,     5.  5.  3    |           Pitschnau-Michel D, Voltz D (2006) Position Paper Palliative
 50   II,     5.  5.  3    |          2006;56(2):78-105~Horakova D (2004): Report of multiple
 51   II,     5.  5.  3    |             36.~Milanov I, Georgiev D, Kmetska K, Jordanova L,
 52   II,     5.  5.  3    | Neuroepidemiology 16:304-307~Miller D, Noseworthy J, Compston
 53   II,     5.  5.  3    |             B, Krtsch U, Burckhardt D, Nordman B (1989): Increasing
 54   II,     5.  5.  3    |            79.~Pritchard C, Baldwin D, Mayers A (2004). Changing
 55   II,     5.  5.  3    |           22.~Rothwell PM, Charlton D (1998): High incidence and
 56   II,     5.  5.  3    |       Trisolini M, Wiener J, Miller D (2002): Principles to promote
 57   II,     5.  5.  3    |             2004; Chio et al, 1998; DAlessandro et al, 1987;
 58   II,     5.  5.  3    |            studies (Schöffski and v.d. Schulenburg, 2007).~ ~PD,
 59   II,     5.  5.  3    |            6.7. References~Aarsland D, Larsen JP, Tandberg E,
 60   II,     5.  5.  3    |             F, Amaducci L, Inzitari D (2000): Parkinson’s disease
 61   II,     5.  5.  3    |         Chio A, Magnani C, Schiffer D (1998): Prevalence of Parkinson’
 62   II,     5.  5.  3    |           Mov Disord 17(2):242-249.~DAlessandro R, Gamberini
 63   II,     5.  5.  3    |              Naccarato S, Manzaroli D (1987): Prevalence of Parkinson’
 64   II,     5.  5.  3    |              Lees A, Rooney C, Burn D (2005): Population based
 65   II,     5.  5.  3    |              250-255~Schöffski O, v.d. Schulenburg J-M., 2007.
 66   II,     5.  5.  3    |            Simonow A, Brandstaedter D, Siebert U, Oertel WH, Ulm
 67   II,     5.  5.  3    |          Neurol 91:133-142.~Twelves D, Perkins KS, Counsell C (
 68   II,     5.  6.  3    |      inactivity, calcium or vitamin D deficiency or corticosteroid
 69   II,     5.  6.  6    |             Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt
 70   II,     5.  6.  6    |         Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke
 71   II,     5.  6.  6    |            JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (
 72   II,     5.  6.  6    |             224-229~Croft P, Coggon D, Cruddas M, Cooper C (1992):
 73   II,     5.  6.  6    |          Ensrud KE, Cauley J, Black D, Vogt TM (1995): Risk factors
 74   II,     5.  6.  6    |     Osteoporos Int 15:38-42~Jonsson D and Husberg M (2000): Socioeconomic
 75   II,     5.  6.  6    |          Levy E, Ferme A, Perocheau D, Bono I (1993): [Socioeconomic
 76   II,     5.  6.  6    |          Lin CT, Albertson G, Price D, Swaney R, Anderson S, Anderson
 77   II,     5.  6.  6    |            B, Nessiøy I, Bruusgaard D, Rutle O (1995): Musculoskeletal
 78   II,     5.  6.  6    |             WE, Harrison B, Symmons D (2001) What is the natural
 79   II,     5.  6.  6    |             Finn JD, Lunt M, Purdie D, Reid DM, Rowe R, Woolf
 80   II,     5.  6.  6    |         Bendall H, Cooper C, Coggon D (2000) Back pain in Britain:
 81   II,     5.  6.  6    |          Sci Med 40:189-197~Symmons D, Harrison B (2000): Early
 82   II,     5.  6.  6    |          Oxford) 39:835-843~Symmons D, Mathers C, and Pfleger
 83   II,     5.  6.  6    |      Organization, Geneva~ ~Symmons D, Turner G, Webb R, Asten
 84   II,     5.  6.  6    |            Barrett E, Lunt M, Scott D, Silman A (2002): The prevalence
 85   II,     5.  6.  6    |            793-800~Urwin M, Symmons D, Allison T, Brammah T, Busby
 86   II,     5.  6.  6    |              Chaussade S, Cucinotta D, Veale DJ, Martin-Mola E (
 87   II,     5.  7.  1    |        Otero et al., 2005; de Zeeuw D et al., 2005; Hallan et
 88   II,     5.  7.  1    |       dialysis or transplantation~5 D if dialysis (HD or PD)~ ~*
 89   II,     5.  7.  7    |       Baigent C, Burbury K, Wheeler D (2000): Premature cardiovascular
 90   II,     5.  7.  7    |              Chen J, Wildman RP, Gu D, Kusek JW, Spruill M, Reynolds
 91   II,     5.  7.  7    |          800-6.~Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers
 92   II,     5.  7.  7    |           Jan;16(1):180-8.~de Zeeuw D, Hillege HL, de Jong PE (
 93   II,     5.  7.  7    |      Chambless L, Merkin SS, Arnett D, Eigenbrodt M, Nieto FJ,
 94   II,     5.  7.  7    |              Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004):
 95   II,     5.  7.  7    |            Greene T, Rogers N, Roth D (1999): A more accurate
 96   II,     5.  7.  7    |       National Kidney Foundation. K/D The seventh report of the
 97   II,     5.  8.  7    |            Kreiss K, Mapp C, Milton D, Schwartz D, Toren K, Viegi
 98   II,     5.  8.  7    |          Mapp C, Milton D, Schwartz D, Toren K, Viegi G (2003):
 99   II,     5.  8.  7    |            Boutin-Forzano S, Moreau D, Kalaboka S, Gay E, Bonnefoy
100   II,     5.  8.  7    |        Carrozzi L, Viegi G, Charpin D, Annesi-Maesano I. (2007) :
101   II,     5.  8.  7    |           Housset B, Huchon G, Huas D, Godard P, Voinet C, Chanal
102   II,     5.  8.  7    |             E, Nicolauu J, Eilstein D, Delmas M-C (2006): Deaths
103   II,     5.  8.  7    |            22: 485-489.~ ~Goodridge D., Lawson J., Duggleby W.,
104   II,     5.  8.  7    |               Duggleby W.,Marciniuk D., Rennie D., Stang M (2008):.
105   II,     5.  8.  7    |             W.,Marciniuk D., Rennie D., Stang M (2008):. Health
106   II,     5.  8.  7    |            16 April 2007)~ ~Gorecka D, Bednarek M, Nowinski A,
107   II,     5.  8.  7    |       Halbert RJ, Isonaka S, George D, Iqbal A (2003): Interpreting
108   II,     5.  8.  7    |   Garcia-Esteban R, Radon R, Jarvis D, Toren K, Künzli N, Norbäck
109   II,     5.  8.  7    |          Toren K, Künzli N, Norbäck D, d'Errico A, Urrutia I,
110   II,     5.  8.  7    |             K, Künzli N, Norbäck D, d'Errico A, Urrutia I, Payo
111   II,     5.  8.  7    |    Zielinski J, Bednarek M, Gorecka D, Viegi G, Hurd SS, Fukuchi
112   II,     5.  9.  4    |          allergen. Sensitization to D. Pteronyssinus, grass pollen
113   II,     5.  9.  4    |             54.8%. Sensitization to D. pteronyssinus, grass pollen
114   II,     5.  9.  7    |            Austin JB, Burr M, Jeffs D (2004): Trends in prevalence
115   II,     5.  9.  7    |       Hooper R, Kogevinas M, Jarvis D, Burney P. (2007a): Nu I.
116   II,     5.  9.  7    |       Kogevinas M, Burney P, Jarvis D (2007b): Ge I. Allergy 62:
117   II,     5.  9.  7    |             2006~ ~Masoli M, Fabian D, Holt S, Beasley R, Global
118   II,     5.  9.  7    |         Germany~ ~Holgate ST, Price D, Valovirta E (2006): Asthma
119   II,     5.  9.  7    |             2466-6-S1-S2).~ ~Jarvis D, Luczynska C, Chinn S, Potts
120   II,     5. 10.  5    |        thereof (including lactose) (d)~- Nuts and products thereof (
121   II,     5. 10.  5    |            from soybean sources.~ ~(d) whey used for making distillates
122   II,     5. 10.  7    |         Gupta R, Sheikh A, Strachan D, Ross Anderson H (2003):
123   II,     5. 10.  7    |         Keil T, Summers C, Gislason D, Zuidmeer L, Sodergren E,
124   II,     5. 11.  1    |              heat and cold. Vitamin D is synthesized in the skin.
125   II,     5. 12.  5    |       developed areas of the world (D'Argenio et al, 1989; Shapiro
126   II,     5. 12.  6    |             is advisable. (Schuppan D, Afdhal NH, 2008)~ ~ ~
127   II,     5. 12.  7    |             Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM,
128   II,     5. 12.  7    |            Hepatology 27:914-919.~ ~D'Argenio P, Esposito D, Mele
129   II,     5. 12.  7    |               D'Argenio P, Esposito D, Mele A, Ortolani G, Adamo
130   II,     5. 12.  7    |                     Negri E, Little D, Boiocchi M, La Vecchia
131   II,     5. 12.  7    |        Messner M, Launois B, Samuel D, Cherqui D, et al (1999):
132   II,     5. 12.  7    |        Launois B, Samuel D, Cherqui D, et al (1999): Evaluation
133   II,     5. 12.  7    |    Endoscopy 34:690-697.~ ~Schuppan D, Afdhal NH (2008): Liver
134   II,     5. 14.  2    |     recommended at age 12 and 15.~ ~d. Edentulous Prevalence~Proportion
135   II,     5. 14.  8    |              Petersen PE, Bourgeois D, Bratthal D, Ogawa H (2005):
136   II,     5. 14.  8    |           PE, Bourgeois D, Bratthal D, Ogawa H (2005): Oral health
137   II,     5. 14.  8    |              Petersen PE, Bourgeois D, Ogawa H, Estupinan-Day
138   II,     5. 15.  6    |          1060.~Kesselman I, Elstein D, Israeli A, Chertkoff R,
139   II,     6.  3.  7    |             2000 from Ghana or Côte dIvoire and Nigeria. No cases
140   II,     6.  3.  7    |            1999 (imported from Côte dIvoire), one from Belgium
141   II,     6.  4.  5    |      controlled way in agriculture; d) reinforce and promote infection
142   II,     7.  7        |    Organization.~ ~Körmer C, Smolka D (2008): Injuries to Vulnerable
143   II,     7.  7        |       Office for Europe.~ ~Schopper D, Lormand JD, Waxweiler R (
144   II,     7.  7        |    Organization.~ ~Shields N, Sethi D, Racioppi F, Yordi Aguirre
145   II,     7.  7        |           Europe.~ ~Todd C, Skelton D. (2004): What are the main
146   II,     8.  2.  1    |         Scheepers M, Kerr M, O’Hara D, Bainbridge D, Cooper S-A,
147   II,     8.  2.  1    |             M, O’Hara D, Bainbridge D, Cooper S-A, Davis R, Fujiura
148   II,     8.  2.  2    |             Eye 19:175-82~Pascolini D, Mariotti S, Pokharel GP,
149   II,     8.  2.  2    |         Pararajasegaram R, Etyaale D, Négrel A-D, et al. (2004):
150   II,     8.  2.  2    |              Resnikoff S, Pascolini D, Etyaale D, Kocur I, Pararajasegaram
151   II,     8.  2.  2    |            S, Pascolini D, Etyaale D, Kocur I, Pararajasegaram
152   II,     8.  2.  2    |          851~Resnikoff S, Pascolini D, Mariotti SP and Pokharel
153   II,     9            |            Tables from 9.1.a to 9.1.d.~ ~Table 9.1a. Main risk
154   II,     9.  1.  1    |            Sibony O, Oury JF, Luton D, Blot P (2002): Differences
155   II,     9.  1.  1    |            8.~Bertollini R, DiLallo D, Spadea T, Perucci C. Cesarean (
156   II,     9.  1.  1    |            Meershoek AP, van Velzen D (1998): Contribution of
157   II,     9.  1.  1    |        Manktelow B, Field DJ, James D (1999): Prediction of survival
158   II,     9.  1.  1    |             SB, Moutquin JM, Farine D, Saigal S, Nimrod C, Kelly
159   II,     9.  1.  1    |        Lorenz JM, Cleary-Goldman J, D'Alton ME, et al (2003):
160   II,     9.  1.  1    |      Reempts P, Gortner L, Milligan D, Cuttini M, Petrou S, Agostino
161   II,     9.  1.  2    |            termination of pregnancy d) the quality of treatment
162   II,     9.  1.  2    |            of hospital episode data d) electronic access to birth
163   II,     9.  1.  2    |            other health benefits.~ ~d) Public health measures
164   II,     9.  1.  2    |      McDonnell R, Nelen V and Stone D (2005c): "Survey of Informed
165   II,     9.  1.  2    |        Haeusler M, Jordan H, Tucker D, Stoll C, Feijoo M, Lillis
166   II,     9.  1.  2    |           Stoll C, Feijoo M, Lillis D, Bianchi F (2005): "Trends
167   II,     9.  1.  2    |        Wiesel A, Calzolari E, Stone D (2004): "Towards the Effective
168   II,     9.  1.  2    |          Vigan C, Scarano G, Tucker D, Stoll C et al (2005): “
169   II,     9.  1.  2    |           Vrijheid M, Dolk H, Stone D, Abramsky L, Alberman E,
170   II,     9.  2.  7    |              References~ ~Alexander D, Rigby M, Hillger C, Neumann
171   II,     9.  2.  7    |             809.~ ~Masoli M, Fabian D, Holt S, Beasley R (2004?):
172   II,     9.  2.  7    |           55-71.~ ~Neumark-Sztainer D; Wall M; Story M; Fulkerson
173   II,     9.  2.  7    |          Ozanne SE, Fernandez-Twinn D, Hales CN (2005): Fetal
174   II,     9.  3.  1    |       intake of calcium and vitamin D – and adequate physical activity
175   II,     9.  3.  1    |      polishing. Calcium and vitamin D supplementation and pharmacologic
176   II,     9.  3.  1    |      European Communities.~ ~Falzon D and Belghiti F (2007): Tuberculosis –
177   II,     9.  3.  1    |           15), pp 363-388~ ~Haslam, D (2007) The causes of male
178   II,     9.  3.  1    |       Health Organization~ ~Wilkins D (2007): Report on the Expert
179   II,     9.  3.  2    |            Sibony O, Oury JF, Luton D, Blot P (2002): Differences
180   II,     9.  3.  2    |               Bertollini R, DiLallo D, Spadea T, Perucci C. Cesarean (
181   II,     9.  3.  2    |            Meershoek AP, van Velzen D (1998): Contribution of
182   II,     9.  3.  2    |        Manktelow B, Field DJ, James D (1999): Prediction of survival
183   II,     9.  3.  2    |             SB, Moutquin JM, Farine D, Saigal S, Nimrod C, Kelly
184   II,     9.  3.  2    |        Lorenz JM, Cleary-Goldman J, D'Alton ME, et al (2003):
185   II,     9.  3.  2    |      mortality statistics. In: Hull D, editor. Recent Advances
186   II,     9.  3.  2    |      Reempts P, Gortner L, Milligan D, Cuttini M, Petrou S, Agostino
187   II,     9.  3.  3    |  information to be effective (Kirby D et al, 2006). Systematic
188   II,     9.  3.  3    |      Observatoire Régional de Santé dIle de France.~Bochow M,
189   II,     9.  3.  3    |      Saint-Louis à Bruxelles Centre d’études sociologiques (2006).
190   II,     9.  3.  3    |            Health Metrics 2:5~Kirby D, Laris BA, Rolleri L (2006):
191   II,     9.  3.  3    |            Singh S, Hodges Z, Patel D, Bajos N (2006): Sexual
192   II,     9.  4.  7    |             S1: S110-S114~ ~Volkert D (2005): Abstract: Nutrition
193   II,     9.  5.  6    |         accessed 12.07.07)~ ~Cutler D, Deaton A, Lleras-Muney
194   II,     9.  5.  6    |          279: 31 January~ ~Jernigan D H (2001): Global Status
195   II,     9.  5.  6    |     Organization, Geneva~ ~Jernigan D H (2001): Global Status
196   II,     9.  5.  6    |           accessed 07.07)~ ~Volkert D (2005): Nutrition and lifestyle
197  III,    10.  1.  3    |            AK, Franklin BA, Buchner D, Daniles SR, Claytor RP (
198  III,    10.  1.  3    |        Nutrition 24:885-895.~Meusel D, Höger C, Pérez-Rodrigo
199  III,    10.  1.  3    |         Geneva, Switzerland.~Meusel D, Maywald U, Hach I, Kirch
200  III,    10.  1.  3    |             71-75.~Wagner N, Meusel D, Höger C, Kirch W (2005):
201  III,    10.  2.  1    |            Marco R, Chinn S, Jarvis D, Svanes C, Heinrich J, Jõgi
202  III,    10.  2.  1    |              Petersen PE, Bourgeois D, Ogawa H, Estupinan-Day
203  III,    10.  2.  1    |           Helakorpi et al., 2003)~ ~d) Lack of information on
204  III,    10.  2.  1    |             June 2007).~ ~Glenister D (1996): Exercise and mental
205  III,    10.  2.  1    |    Physiology, 99:765770.~ ~Hunter D (2005): Proceedings of the
206  III,    10.  2.  1    |          Turrini A, Saba A, Perrone D, Cialfa E, D'Amicis A (2001):
207  III,    10.  2.  1    |             A, Perrone D, Cialfa E, D'Amicis A (2001): Food consumption
208  III,    10.  2.  1    |       Scandinavian countries, 300µg/d of folate are recommended
209  III,    10.  2.  1    |             vitamin B12 .~ ~Vitamin D and Calcium~ ~Vitamin D
210  III,    10.  2.  1    |             D and Calcium~ ~Vitamin D differs from other vitamins
211  III,    10.  2.  1    |           is intensified by vitamin D deficiency increasing the
212  III,    10.  2.  1    |       ability to synthesize vitamin D also declines with age (
213  III,    10.  2.  1    |             Food sources of vitamin D are rather scarce with fish
214  III,    10.  2.  1    |        supply is often below 800 mg/d (Eurodiet 2000). The elderly
215  III,    10.  2.  1    |       suffer from a lack of vitamin D as previously mentioned.
216  III,    10.  2.  1    |            Intake (DRI)).~o Vitamin D. Because it is inexpensive
217  III,    10.  2.  1    |      inexpensive to provide vitamin D and because many of the
218  III,    10.  2.  1    |           calcium also used vitamin D supplementation, supplements
219  III,    10.  2.  1    |              supplements of vitamin D are recommended for at-risk
220  III,    10.  2.  1    |     international units) of vitamin D per day may be sufficient.~
221  III,    10.  2.  1    |           adequate calcium, vitamin D and iron supply. Deficiencies
222  III,    10.  2.  1    |   insufficient for vitamins B12 and D and for iron. Further emerging
223  III,    10.  2.  1    |            30:12651271.~ ~Jotangia D, Moody A, Stamatakis E,
224  III,    10.  2.  1    |           Journal 309:57.~ ~Mansour D (2004): Implications of
225  III,    10.  2.  1    |          examination surveys. Revue dEpidémiologie et de Santé
226  III,    10.  2.  1    |         Jēce I, Velika B, Grīnberga D, Villeruša A, Dzērve V,
227  III,    10.  2.  1    |        Mozsáry E, Vitrai J, Hermann D, Boros J, Németh R, Kéki
228  III,    10.  2.  1    |          2001): Calcium and vitamin D nutrition and bone disease
229  III,    10.  2.  1    |           Kroke A, Bamia C, Karalis D, Vineis P, Palli D, Bueno-de-Mesquita
230  III,    10.  2.  1    |          Karalis D, Vineis P, Palli D, Bueno-de-Mesquita HB, Peeters
231  III,    10.  2.  1    |             HB, Peeters PH, Engeset D, Hjartaker A, Navarro C,
232  III,    10.  2.  1    |             MC, Peeters PH, Engeset D, Skeie G, Aller A, Amiano
233  III,    10.  2.  1    |          van der Schouw YT, Engeset D, Skeie G, Tormo MJ, Ardanaz
234  III,    10.  2.  1    |        Peeters PH, Skeie G, Engeset D, Charrondiere UR, Slimani
235  III,    10.  2.  1    |             MC, Peeters PH, Engeset D, Skeie G, Slimani N, Riboli
236  III,    10.  2.  4    |          969-974.~ ~Childs B, Valle D (2000): Genetics, Biology
237  III,    10.  2.  4    |            Dudas ME, Leung DHY, Kuo D, Brennan MF, Lewis JJ, Cordon-Cardo
238  III,    10.  2.  4    |           158:1245-1251.~ ~Ibarreta D, Bock, A.K., Klein C, Rodriguez-Cerezo
239  III,    10.  2.  4    |   Cortina-Borja M, Warden DR, Smith D, Sleegens K, Prince JA,
240  III,    10.  2.  4    |        Bracci PM, Cerhan JR, Whitby D, Moore PS, Leaderer B, Lai
241  III,    10.  2.  5    |          Forsen T, Osmond C, Barker D, Eriksson J (2001): Association
242  III,    10.  3.  1    |            the synthesis of vitamin D in the skin. Vitamin D is
243  III,    10.  3.  1    |      vitamin D in the skin. Vitamin D is essential for the metabolism
244  III,    10.  3.  1    |             in the body and vitamin D deficiency leads to de-calcification
245  III,    10.  3.  1    |           38, 99-166.~Darby S, Hill D, Auvinen A, Barros-Dios
246  III,    10.  3.  1    |         Leuraud K, Billon S, Bergot D, Tirmarche M, Caër S, Quesne
247  III,    10.  3.  1    |           Caër S, Quesne B, Laurier D (2007): Lung cancer risk
248  III,    10.  3.  1    |     Berglund B, Lindvall T, Schwela D.~World Health Organization
249  III,    10.  4.  2    |          the food production chain; d) food safety: limits on
250  III,    10.  4.  2    |     experienced staff are present; (d) that they have appropriate
251  III,    10.  5.  1    |          2001, 285:535539.~Norback D, Tao J, Mi YL, Ferm M, (
252  III,    10.  5.  1    |            Wang Z, Zhang Z, Norbäck D, (2008): Asthmatic symptoms
253  III,    10.  5.  2    |                O'Reilly G, O'Reilly D, Rosato M, Connolly S (2007):
254  III,    10.  5.  3    |         University Press.~ ~Walters D (2007): An International
255  III,    10.  6.  1    |          Roberts C, Smith R, Currie D, Picket W, Richter M, Morgan
256   IV,    11.  1.  3    |      purchasing from provision; and d) reforming payment mechanisms.~ ~
257   IV,    11.  6.  4    |          Cotisations de Sécurité et dAllocations Familiales at
258   IV,    11.  6.  5    |           Communities.~ ~Balabanova D, McKee M (2002): "Understanding
259   IV,    11.  6.  5    |             3): 10-20.~ ~Blumenthal D (1996): "Part 1: Quality
260   IV,    11.  6.  5    |             9.~ ~Claridge T, Parker D et al. (2006): Pathways
261   IV,    11.  6.  5    |            XL: 881-906.~ ~De Graeve D, Van Ourti T (2003): The
262   IV,    11.  6.  5    |      eurobarometers_en.htm.~ ~Evans D, Edejer T et al. (2001): "
263   IV,    11.  6.  5    |            OECD.~ ~Kelly MP, McDaid D et al. (2005): Economic
264   IV,    11.  6.  5    |            Paper No. 13.~ ~McCarthy D, Blumenthal D (2006): Committed
265   IV,    11.  6.  5    |              McCarthy D, Blumenthal D (2006): Committed to Safety:
266   IV,    11.  6.  5    |         Commonwealth Fund.~ ~McDaid D, Knapp M et al. (2005):
267   IV,    11.  6.  5    |      Systems and Policies.~ ~McDaid D, Thornicroft G (2005): Mental
268   IV,    11.  6.  5    |          205.~ ~Mossialos E, Brogan D et al. (2006): "Pharmaceutical
269   IV,    11.  6.  5    |             361: 1817-20.~ ~Navarro D (2000): "Assessment of the
270   IV,    11.  6.  5    |             108.~ ~Retzlaff-Roberts D, Chang CF et al. (2004): "
271   IV,    11.  6.  5    |           76.~ ~Rizzo J, Blumenthal D (1996): "Is the target income
272   IV,    11.  6.  5    |          and Policies.~ ~Sappington D (1991): "Incentives in Principal-Agent
273   IV,    12. 10        |         2006 Campaign: FA C T S A N D A D V I C E~about smoking
274   IV,    12. 10        |          Campaign: FA C T S A N D A D V I C E~about smoking and
275   IV,    12. 10        |        vegetables, preferably 600 g/d for adults and children (>
276   IV,    12. 10        |             years of age) and 400 g/d for children (4-10 years
277   IV,    13.  7.  2    |             private investment in R&D; location advantages for
278   IV,    13.  7.  2    |           location advantages for R&D and production facilities;